Funds and ETFs Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 24/06/2024 BST 5-day change 1st Jan Change
1,064 USD +1.02% Intraday chart for Regeneron Pharmaceuticals, Inc. +1.77% +21.13%

ETFs positioned on Regeneron Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.71% 3 M€ 0.00% -
0.66% 379 M€ +10.41%
0.47% 330 M€ -.--% -
0.43% 36 M€ -.--%
0.42% 1,448 M€ -.--% -
0.42% 219 M€ +17.17% -
0.42% 23 M€ +14.99%
0.38% 1,174 M€ +23.54%
0.38% 655 M€ -.--% -
0.38% 273 M€ -.--%
0.35% 1 M€ +0.04%
0.35% 391 M€ +30.54% -
0.33% 276 M€ +11.40% -
0.32% 1,848 M€ -.--% -
0.32% 559 M€ -.--% -
0.30% 26 M€ +28.93% -
0.30% 825 M€ +13.70%
0.30% 9 M€ +9.80% -
0.29% 1 M€ -.--%
0.28% 55 M€ +14.69%
0.27% 7 M€ +0.11% -
0.24% 6 M€ +17.98% -
0.24% 205 M€ -.--%
0.24% 9 M€ +10.87% -
0.24% 133 M€ +9.98% -
0.23% 18 M€ +4.86% -
0.23% 35 M€ +13.48% -
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,064 USD
Average target price
1,051 USD
Spread / Average Target
-1.17%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Funds and ETFs Regeneron Pharmaceuticals, Inc.